On April 30, 2026, the U.S. Food and Drug Administration issued a formal proposal that, if finalized, would permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. The proposal is procedural — it opens a public comment period rather than imposing an immediate ban — but its practical effect would be to close the last remaining legal pathway for FDA-registered outsourcing facilities to compound these blockbuster GLP-1 medications at industrial scale.
This is a separate regulatory action from the April 15, 2026 announcement that removed twelve healing peptides (BPC-157, TB-500, KPV, MOTS-c, and others) from Category 2, and from the upcoming July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting that will decide whether several of those peptides should be added to the 503A Bulks List. We covered both of those in our FDA peptide reclassification 2026 guide. The 503B GLP-1 proposal travels in a different lane and applies to different facilities, peptides, and patient access pathways.
The public comment period closes June 29, 2026. Below is a plain-English breakdown of what the FDA is proposing, why it matters for the three GLP-1s in question, and what consumers, prescribers, and the compounded-medication industry can reasonably anticipate next.
What the April 30, 2026 Proposal Actually Says
The FDA's proposal targets one specific regulatory mechanism: the 503B Bulks List. Outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act may compound from a bulk drug substance only if (a) the substance appears on FDA's official 503B Bulks List, or (b) the corresponding finished drug is on FDA's Drug Shortage List. Until early 2025, semaglutide and tirzepatide both qualified under the second pathway because of documented national shortages. Liraglutide was previously available through similar pathways for selected formulations.
The shortages have been resolved — semaglutide officially in February 2025, tirzepatide in December 2024 — and FDA has now moved to formally rule out the first pathway as well. In the agency's stated reasoning, there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk active pharmaceutical ingredient when fully approved branded versions are commercially available from Novo Nordisk and Eli Lilly. The proposal would lock that determination into the 503B Bulks List on a permanent basis rather than leaving it as an enforcement-discretion question.
If finalized, the rule would eliminate the principal industrial-scale legal route to compounded GLP-1s. It would not retroactively make compounded GLP-1s already in patients' refrigerators illegal, and it would not affect prescribed branded Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, or Victoza in any way. Those approved products remain fully available through ordinary pharmacy channels.
503A vs. 503B: Why the Distinction Matters Here
Compounding pharmacies operate under two very different sections of federal law, and this proposal applies to only one of them. The distinction is essential to understanding what is actually changing.
Section 503A — Traditional Compounding Pharmacies
503A pharmacies are state-licensed compounding pharmacies that prepare medications for individual patients with patient-specific prescriptions. They are regulated primarily by state pharmacy boards. Under federal law, 503A pharmacies are exempt from certain manufacturing requirements when they meet a series of conditions, including that the product is not "essentially a copy" of a commercially available drug — a standard that has been the subject of extensive litigation in the GLP-1 context.
503A pharmacies are not directly affected by the April 30 proposal. Whether a specific 503A pharmacy may continue to compound a GLP-1 for a specific patient depends on the prescriber's documented clinical-difference determination, the state pharmacy board's interpretation, and any active court orders in the relevant jurisdiction. Some federal court injunctions issued in 2025 and early 2026 have temporarily restrained certain FDA enforcement actions in this area, and the legal landscape is still being shaped case by case.
Section 503B — Outsourcing Facilities
503B outsourcing facilities are FDA-registered, FDA-inspected establishments that may compound at larger volumes without patient-specific prescriptions. They function as small-scale manufacturers and are subject to Current Good Manufacturing Practice (cGMP) requirements similar to commercial drug manufacturers. The 503B pathway has historically supplied hospital systems, large clinics, and telehealth networks that needed compounded medications at scale.
The April 30 proposal applies directly to 503B facilities. If the rule is finalized as proposed, no 503B outsourcing facility would have a federal legal basis to compound semaglutide, tirzepatide, or liraglutide from bulk API for general supply. The only remaining narrow path under federal law would be patient-specific compounding through 503A pharmacies, subject to the constraints described above.
The practical implication: a substantial portion of the compounded GLP-1 supply that has flowed through telehealth platforms and large clinic networks in 2024 and 2025 was produced or distributed via 503B pathways. That supply route is what this proposal would close.
Why the FDA Is Doing This Now
The FDA's stated rationale rests on three observations. First, semaglutide and tirzepatide are no longer on the Drug Shortage List, which removes the original statutory justification for compounding under shortage exceptions. Second, the brand-name manufacturers (Novo Nordisk and Eli Lilly) have demonstrated sustained ability to supply the U.S. market at scale. Third, FDA has documented patient safety issues associated with compounded GLP-1 products — over 455 adverse event reports linked to compounded semaglutide and 320 reports linked to compounded tirzepatide as of early 2025, with many cases involving dosing errors from patients self-administering incorrect volumes from multidose vials.
The proposal also reflects the agency's consistent position throughout 2024 and 2025 that bulk-substance compounding of GLP-1s presents quality, sterility, and identity-testing concerns that are not adequately addressed outside the cGMP framework that applies to FDA-approved manufacturers. A 2024 analysis of compounded semaglutide samples from unregulated online sellers found that only roughly 30 percent met basic quality standards, with assayed strengths ranging from approximately 0.4 percent to over 300 percent of labeled values — a spread that has clear potential for clinical harm.
What This Means for Patients
For patients currently taking branded Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, or Victoza, this proposal changes nothing. Approved products remain fully available, and the proposal explicitly does not affect approved-drug supply.
For patients currently obtaining compounded semaglutide, tirzepatide, or liraglutide through telehealth platforms or compounding-network arrangements, the picture is more variable. If a patient's compounded medication is being supplied through a 503B outsourcing facility relying on the previously-available shortage pathway, that supply route may have already wound down or may wind down further during the comment period and any subsequent rulemaking. If the medication is being supplied through a 503A pharmacy on a patient-specific basis with a documented clinical-difference determination by the prescriber, the legal status depends on factors unique to that prescriber-patient-pharmacy relationship.
Patients in either category should not stop a prescribed medication based on news reporting about regulatory proposals. Decisions about continuing, switching, or discontinuing GLP-1 therapy should be made in consultation with the prescribing clinician, who will have visibility into the specific supply chain and applicable legal constraints for that patient's regimen. Where access to a compounded product becomes restricted, transitioning to an FDA-approved branded product — with appropriate dose-equivalence guidance from the prescriber — is generally the recommended approach.
What This Means for the Compounded GLP-1 Industry
The proposal, if finalized, would constrain the business model that supported much of the compounded GLP-1 market over the past three years. The price gap between branded GLP-1s (typically $900–$1,400 per month at list price for Ozempic and Wegovy) and compounded versions ($129–$299 per month through telehealth platforms) had been the primary commercial driver of compounded supply. With the principal 503B pathway closing and 503A pathways constrained, the volume available through compounded channels is likely to contract substantially.
Several compounding industry stakeholders have signaled they will submit comments during the public comment period, and some have indicated potential legal challenges if the rule is finalized as drafted. Multiple lawsuits filed by compounding pharmacies, telehealth companies, and industry associations in 2024–2025 challenging FDA's interpretation of the "essentially a copy" standard remain pending in federal court. Court rulings during the comment period could meaningfully alter the trajectory of the proposal or affect how it is implemented.
Novo Nordisk and Eli Lilly have continued to expand patient-affordability programs, manufacturing capacity, and direct-to-patient pharmacy options for their branded products. Whether those measures meaningfully reduce the access gap that drove compounded demand remains a matter of ongoing observation.
Comment Period and Next Steps
The public comment period for the April 30 proposal closes on June 29, 2026. Comments may be submitted through the official FDA docket associated with the proposal. After the comment period, FDA will review submissions and issue either a final rule, a revised proposed rule, or a withdrawal of the proposal — with no fixed timeline for that decision.
Two related FDA activities are scheduled in parallel and worth tracking. The Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to evaluate seven peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon — for possible inclusion on the 503A Bulks List. That meeting concerns the healing-peptide universe rather than the GLP-1s and is procedurally separate from the April 30 proposal. A second PCAC meeting is scheduled before the end of February 2027 for further bulk-substance review.
How We Will Update This Page
We will update this page when material developments occur: when the FDA issues a final rule, when a court ruling materially affects the proposal's enforceability, or when the underlying drug-approval, shortage-list, or compounding-status of any of the three GLP-1s discussed here changes. Where appropriate, we will also update the regulatory-status sections of our individual semaglutide and tirzepatide profile pages to reflect the latest position.
For background on the broader legal landscape for compounded GLP-1s, see our compounded semaglutide 2026 guide and our peptide legality complete guide.
This article is for informational purposes only and does not constitute medical or legal advice. The regulatory landscape described here is evolving and varies by jurisdiction. Specific legal questions should be directed to a qualified attorney. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.